Lupin pulls over 9,000 bottles of anti-infective Suprax from US

Lupin Ltd is recalling 9,210 bottles of infection-preventing drug Suprax which failed a purity

RELATED ARTICLES

test in the United States, the US Food and Drug Administration said.

The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the U.S. in January last year because of discoloration.

Recalls are not uncommon among drugmakers. This year alone, recalls have been conducted by all of Lupin's bigger local rivals - Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd and Dr. Reddy's Laboratories Ltd.

The latest recalled bottles of Suprax, used to prevent or treat bacteria-related infection, "did not meet specification in total impurities", the FDA said on its website on Monday.

The FDA classified the incident as a Class III recall, meaning use of or exposure to the drug is unlikely to cause any adverse health consequences.

A Lupin spokesperson on Tuesday confirmed the recall, which began in January, and said the company expects "no business consequence".

The recent recalls come amid increased FDA scrutiny of medicines produced in India, which supplies about 40 percent of generic and over-the-counter drugs sold in the U.S.

Indian drugmakers are heavily reliant on the U.S. where Lupin, for instance, derives around 40 percent of sales.

In September, Lupin also recalled over 53,000 bottles of hypertension drug quinapril from the US.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Copy the characters (respecting upper/lower case) from the image.

EDITORIAL OF THE DAY

  • State-owned banks can ride technology surge to penetrate retail segment

    For the first time in recent history, two large private sectors banks, ICICI and Axis have reduced their headcounts.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Roopen Roy

Livability as a competitive advantage

Some CEOs and policymakers argue forcefully that distance is of ...

Rajgopal Nidamboor

The submarine element of your mind

We are all aware of the power of our will ...

Gautam Gupta

Retailers have it tough, thanks to e-commerce

For the past few months our focus has been on ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture